HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $45 to $58.
March 14, 2024 | 10:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Mirum Pharmaceuticals and increases the price target from $45 to $58.
The upgrade in the price target from $45 to $58 by a reputable analyst firm like HC Wainwright & Co. suggests a strong confidence in Mirum Pharmaceuticals' future performance. This positive analyst action is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100